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Down-Regulation of IFN-–Producing CD56 T Cells
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Treatment in Patients with Behçet’s Uveitis
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Hyeong Gon Yu1
PURPOSE. To investigate the effects of combined low-dose cy-
closporine and prednisone (Cs/Pd) treatment on circulating
CD56 T cells in patients with Behçet’s uveitis.
METHODS. Ten patients with Behçet’s uveitis and 10 healthy
control subjects were prospectively recruited. The patients
were treated with Cs/Pd for 2 months. Phenotypic and func-
tional changes in circulating CD56 T cells were assayed be-
fore and after treatment. CD56 T-cell subsets were deter-
mined by flow cytometric analysis with monoclonal antibodies
for CD3, CD4, CD8, CD56, pan  TCR, and V24. The abso-
lute numbers of cells in the lymphocyte subsets were calcu-
lated. Cytokine (IFN-, IL-4, and IL-10) expressions were mea-
sured by ELISA and by intracellular cytokine staining.
RESULTS. The proportions of CD56 T cells, specifically
CD8highCD56 and CD56 T-cell subsets, were significantly
higher in active Behçet’s uveitis but normalized after treat-
ment, whereas the total T-lymphocyte count and the absolute
numbers of CD56 T cells were unaffected by treatment. The
levels of IFN- and IL-4 were elevated in aqueous humor and
serum in Behçet’s uveitis (P  0.001), whereas IL-10 was not
detected. After treatment, serum IL-4 levels markedly increased
(P  0.001), and IFN- production by circulating CD56 T
cells was then suppressed. IL-4 and -10 production by CD56
T cells was increased by treatment, but in contrast, minimal
changes were found in CD56 T cells.
CONCLUSIONS. The results imply that Cs/Pd treatment for Beh-
çet’s uveitis selectively affects the population of and the cyto-
kine expression in CD56 T cells, but without significant
changes in CD56 T cells, and that IFN-–producing CD56 T
cells are the central pathogenic immune cells in Behçet’s
uveitis. (Invest Ophthalmol Vis Sci. 2005;46:2458–2464) DOI:
10.1167/iovs.04-0792
Behçet’s uveitis, a prototype of chronic recurrent uveitiswith retinal vasculitis, is often accompanied by multisys-
temic manifestations in the mucocutaneous, arthritic, vascular,
and central nervous systems.1 Although various primary im-
mune abnormalities involving genetic, infectious, and autoim-
mune components have been implicated in Behçet’s disease,
much remains uncertain about its pathogenesis.2–4 Both innate
and adaptive immune responses have been suggested to play a
pathogenic role in Behçet’s disease.5,6 Aberrant cellular immu-
nity, such as T-cell-mediated autoimmunity or an imbalance in
the Th1/Th2 pathway, may be crucial in the pathogenesis of
Behçet’s disease.7,8 Recently, CD56 T cells were reported to
be higher in the aqueous humor and peripheral blood of
patients with Behçet’s uveitis than were other endogenous
uveitides.9,10
Surface CD56 (neuronal cell adhesion molecule), a receptor
for natural killer (NK) cells, is found on heterogeneous T-cell
subsets, such as CD4, CD8,  T, and V24 T cells in
humans.11 CD56 is also induced on cytotoxic  or  T cells
by TCR stimulation in a Th1-rich environment.12 In a study of
T-cell autoimmunity in diabetes mellitus, CD56 T-cell subsets
were found to be more autoaggressive effector cells than their
CD56 counterparts.13 One striking property of these CD56
T cells is their ability to produce both Th1 and Th2 cytokines
(IFN-, TNF-, IL-4, and IL-10) rapidly on TCR engagement at
inflammatory sites.14
Cyclosporine (Cs) is widely used to treat immune-mediated
ocular disorders and seems particularly useful for treating pa-
tients with bilateral, sight-threatening uveitis of a noninfectious
origin.15 Cs is thought to inhibit calcium-dependent T-cell
activation therapeutically and to block the genetic expression
of cytokines,16 and is known to be effective for treating severe
refractory bilateral uveitis, such as Behçet’s disease, usually in
combination with prednisone (Pd). Sugi-Ikai et al.17 reported
that effective Cs treatment in patients with Behçet’s decreases
the populations of IL-2- and IFN-–producing T cells. However,
phenotypic and functional changes of CD56 T cells in pa-
tients with Behçet’s uveitis after immunosuppressive treat-
ments, have not been prospectively monitored. In this study,
we investigated the population changes in lymphocyte subsets
and cytokine status (IFN-, IL-4, and IL-10) in patients with
Behçet’s uveitis after Cs/Pd treatment.
METHODS
Patient Selection
Patients with complete Behçet’s disease (according to the criteria of
the Japanese Behçet’s disease research committee18) and active panu-
veitis were recruited from the uveitis clinic at Seoul National University
Hospital from March 2002 to October 2003. Other etiologies were
excluded after a complete ocular and systemic examination. Patients
who had used corticosteroids (topical, oral, or intravenous) or immu-
nosuppressive agents such as Cs within 1 month of the study’s com-
mencement were also excluded. All patients had an active intraocular
inflammation (anterior chamber cells 2). Aqueous and blood sam-
ples were obtained before the start of any topical or systemic treat-
ment. All tenets of the Declaration of Helsinki were adhered to,
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approval was received from the Investigational Review Board of the
Seoul National University Clinical Research Institute, and informed
consent was obtained from all patients and healthy control subjects.
Ten patients with Behçet’s were recruited for the study (Table 1).
Baseline immunologic studies on population changes of lymphocyte
subsets and cytokine status (IFN-, IL-4, and IL-10) were performed
before Cs (3 mg/kg per day) and Pd (0.4 mg/kg per day) treatment.
Doses were adjusted according to clinical responses and side effects.
Topical corticosteroid therapy was combined with systemic treatments
in all patients, whereas periocular corticosteroid (triamcinolone, 40
mg) were used in only one patient after the baseline immunologic
study. After 2 months of combined low-dose Cs/Pd treatment, immu-
nologic measurements were repeated in each patient. Ten age- and
sex-matched healthy control subjects were used for comparison
purposes.
Phenotypic Analysis of Circulating
CD56 T Lymphocytes
Ten milliliters of heparinized venous blood was obtained from each
patient before and after treatment and also from healthy control sub-
jects. Serum was stored at 70°C until used in cytokine ELISA. Periph-
eral blood mononuclear cells (PBMCs) were isolated by centrifugation
at 400g on a single-density gradient (Ficoll-Hypaque; Amersham Phar-
macia Biotech, Piscataway, NJ). PBMCs were recovered from the buffy
coat layer and washed twice to remove red blood cells. Surface phe-
notypes of cells were identified with monoclonal antibodies (mAbs) in
conjunction with a three- or four-color staining method. Tube A con-
tained isotype-matched control mAbs; tube B contained mAbs directed
toward CD3 (FITC)/CD4 (APC)/CD8 (Cy-Chrome)/CD56 (PE); tube C
contained CD3 (PerCP)/CD56 (FITC)/TCR- (PE); and tube D con-
tained CD3 (PerCP)/CD56 (FITC)/V24 (PE). Aliquots (100 L) of cells
were placed in round-bottomed polystyrene tubes, and the directly
conjugated mAbs were added at predetermined optimal dilutions. After
a 30-minute incubation, aliquots were washed twice in flow cytometry
buffer (phosphate-buffered saline with 0.2% bovine serum albumin;
FACS; BD Biosciences, San Jose, CA). All mAbs were purchased from
BD Biosciences, and data was acquired with their flow cytometer and
software (FACSCalibur and Cell Quest; BD Biosciences) and analyzed
on computer. The absolute numbers of lymphocytes in each subset
were calculated from complete blood counts and from relative pro-
portions of flow cytometry data. Because CD56 expression levels may
be divided into the CD56dim and CD56bright proportions, we also
measured the mean fluorescence intensities (MFIs) of CD56 in
CD8highCD56 T cells and CD56 T cells.
Intracellular Cytokine Staining
Cytokine (IFN-, IL-4, and IL-10) production by circulating CD3,
CD8high, and  T cells (with versus without CD56) was determined by
intracellular cytokine staining according to previously described pro-
cedures.19 Briefly, PBMCs (106/well) were stimulated in a 96-well
round-bottomed plate containing phorbol myristate acetate (PMA, 50
ng/mL; Sigma-Aldrich, St. Louis, MO) and calcium ionomycin (1 M;
Sigma) for 6 hours at 37°C. Intracellular cytokine detection was opti-
mized by activating cells in the presence of 1 M brefeldin A (BD
Biosciences), thereby preventing cytokine secretion and allowing in-
tracytoplasmic accumulation. Unstimulated control wells were incu-
bated with brefeldin A alone. Cells were fixed with 4% paraformalde-
hyde at the end of a 6-hour incubation period. They were also
permeabilized with a wash solution containing saponin (Perm/Wash;
BD Biosciences) to allow intracellular access of PE-labeled anti-cyto-
kine mAbs. For negative control experiments, cells were stained with
PE-labeled isotype-matched control mAbs. For phenotype staining,
cells were incubated for 30 minutes at 4°C with mAbs directed toward
CD3 (PerCP), CD8 (cytochrome), TCR- (APCs), and CD56 (FITC) in
flow cytometry buffer (FACS; BD Biosciences). They were immediately
analyzed on the flow cytometer and the data were processed by the
accompanying software (CellQuest; BD Biosciences). In both unstimu-
lated and stimulated wells, analysis gates were set for lymphocytes
using forward- and side-scatter properties, and the frequencies of
cytokine producing cells were calculated by phenotype gating using
anti-CD3, anti-CD8, anti-TCR-, and anti-CD56. A gating histogram was
determined for each cytokine using isotype controls and unstimulated
control wells (Fig. 1).
Cytokine ELISA in Aqueous Humor and Serum
Aqueous humor was sampled from all patients before treatment and
from 10 healthy control subjects during cataract surgery. Aqueous
humor (200–300 L) was immediately aliquoted into three microfuge
tubes precoated with EDTA to prevent cell clumping. Aqueous sam-
ples were then centrifuged at 400g for 5 minutes at 4°C. Supernatants
were stored at 0°C until required for cytokine ELISA. Serum samples
were thawed only once immediately before cytokine assay. To mea-
sure IFN-, IL-4, and IL-10, we used sandwich ELISAs specific for each
human cytokine. The minimum detectable concentration of each cy-
tokine was as follows: IFN-, 1.5 pg/mL; IL-4, 1.5 pg/mL; and IL-10, 1.5
pg/mL. OD450nm of diluent controls were subtracted to construct
standard curves.
Statistics
Differences in the phenotypic expressions of lymphocytes and cyto-
kine levels between 10 patients with Behçet’s uveitis and 10 healthy







Doses of Cs/Pd (mg/kg)
Chamber Cells
(Pre/Post)‡Initial 1 mo 2 mo
M/43 B panuveitis T  S  C† 3/0.4 4/0.4 5/0.3 3/1
M/39 B panuveitis T  S  C 3/0.4 4/0.4 5/0.4 4/3
M/47 B panuveitis T  S  C 3/0.4 4/0.4 5/0.3 2/1
F/30 B panuveitis T  S  C 3/0.4 4/0.4 5/0.4 3/2
F/21 R panuveitis T 3/0.4 3/0.3 3/0.2 3/1
M/31 R panuveitis C 3/0.4 4/0.4 5/0.3 3/1
M/37 B panuveitis C 3/0.4 4/0.4 5/0.3 4/1
F/40 B panuveitis C 3/0.4 3/0.3 3/0.2 3/0
M/38 B panuveitis — 3/0.4 3/0.3 3/0.2 3/0
M/33 B panuveitis — 3/0.4 4/0.4 5/0.4 4/2
B, bilateral disease; R, right eye disease; T, topical steroids; S, systemic steroids; C, colchicines.
* All previous treatments had been stopped at least 1 month before combined Cs/Pd treatment.
† Anterior chamber cells were evaluated immediately before combined Cs/Pd treatment and 2 months
later.
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control subjects were compared by the nonparametric Mann-Whitney
test. In addition, the Wilcoxon matched-pair signed-rank test was used
to identify differences between values obtained before and after treat-
ment in the 10 patients. P  0.05 was considered significant.
RESULTS
Normalization of CD56 T-Cell Populations in
Patients with Behçet’s Uveitis by Cs/Pd Treatment
The populations of CD56 T cells, especially in the subsets
CD8highCD56 and CD56 T cells, were significantly in-
creased in the peripheral blood of patients with active Behçet’s
uveitis versus control subjects (Table 2). After Cs/Pd treatment,
the populations of CD56 T-cell subsets normalized (Table 2;
Fig. 2). In patients and healthy control subjects, CD56 T cells
were separated on the basis of CD56 expression, and the
CD56bright cells dominated CD8highCD56 T cells, whereas
CD56dim cells dominated CD56  T cells. Furthermore, the
MFIs of CD56 on CD56 T-cell subsets were also significantly
higher at the pretreatment stage than in healthy control sub-
jects and returned to normal levels after treatment (MFI: for
CD8high, 427  49 vs. 308  43 and 334  48; for , 59  5
vs. 47  3 and 51  2, respectively). In contrast, total T-
lymphocyte counts and the absolute numbers of CD3CD56
cells were no different before and after treatment in patients
with Behçet’s. The population of CD4CD56 cells was de-
pressed before treatment, but recovered to a normal level after
treatment. The number of CD8highCD56 cells and
V24CD56 cells was similar in patients and healthy control
subjects and did not change after treatment (Table 2). How-
ever, CD56 T cells were significantly increased in the
peripheral blood of patients with active Behçet’s uveitis versus
control subjects and then decreased after Cs/Pd treatment
(Table 2). Given that topical steroids may inhibit the activation
of lymphocytes by downregulating ocular inflammation, we
measured the proportions of lymphocytes subsets in the pe-
ripheral blood of 10 patients with idiopathic anterior uveitis
before and after 4 weeks of topical steroid treatment. We
found that the proportions of lymphocyte subsets such as
FIGURE 1. Analysis gates and histo-
grams for cytokine producing cells.
(A) Unstimulated cells were gated
on lymphocytes preincubated with
anti-CD3 and anti-CD56. (B) After a
6-hour stimulation with phorbol my-
ristate acetate (50 ng/mL) and cal-
cium ionomycin (1 M), stimulated
cells were gated as described for un-
stimulated cells. (C) Histograms illus-
trating intracellular cytokine staining
obtained without stimulation (thin
trace) gated on R1  R2, and after
stimulation (thick trace) gated on
R3  R4, and mouse IgG1-negative
isotype control (broken trace). Cells
of patients with Behçet’s uveitis
stained for IFN-, whereas cells of
patients with atopic dermatitis
stained for IL-4.
TABLE 2. The Phenotypic Changes of Lymphocyte Subsets in Patients with Behçet’s Uveitis before and








CD3CD56 71.1  5.1 (1568  289) 59.9  8.2 (1441  310) 68.7  11.6 (1602  228)
CD4 44.4  6.9 (986  259) 31.6  6.2 (762  208)* 39.3  7.2 (914  121)†
CD8high 23.0  4.7 (499  102) 24.5  5.3 (587  147) 25.4  7.3 (597  181)
 TCR 69.4  7.3 (1488  145) 54.9  6.3 (1325  121)* 64.7  7.3 (1527  141)†
 TCR 2.9  2.5 (65  58) 5.2  2.0 (125  52)* 3.3  1.6 (75  36)†
V24 0.8  0.2 (12  5) 1.0  0.4 (15  7) 0.9  0.2 (14  4)
CD3CD56 4.0  1.7 (80  32) 12.7  5.8 (296  114)* 4.3  0.9 (100  24)
CD4 0.4  0.3 (9  7) 0.7  0.3 (16  6)* 0.3  0.1 (7  4)†
CD8high 2.0  1.0 (40  22) 6.9  3.4 (160  71)* 2.1  0.6 (49  14)†
 TCR 2.3  1.1 (48  23) 7.2  3.1 (171  63)* 2.5  1.0 (54  20)†
 TCR 1.8  1.1 (36  22) 5.8  4.0 (136  85)* 2.0  1.1 (46  24)†
V24 0.1  0.1 (2  1) 0.2  0.2 (3  3) 0.1  0.1 (2  2)
Data are expressed as the percentage of total lymphocytes, with the absolute number of cells in
parentheses (mean  SD cells/mm2). Significant difference from healthy controls (*) or pretreatment
values (†).
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CD56 T cells were similar before and after treatment in these
patients (data not shown).
Suppression of IFN- Production by Circulating
CD56 T Cells by Cs/Pd Treatment
The number of circulatory CD56 T cells producing IFN- was
higher before treatment in patients with Behçet’s than in
healthy control subjects. In contrast, the percentage of IL-4–
and -10–producing cells was lower (Table 3; Fig. 3). After
Cs/Pd treatment, the percentage of IFN-–producing CD56 T
cells was significantly reduced (47%  13% vs. 29%  21%),
whereas the percentage of IL-4– and -10–producing CD56 T
cells was significantly increased (0.4  0.2% versus 3.4% 
1.5% for IL-4; 0.7%  0.3% versus 3.0%  2.4% for IL-10; Table
3; Fig. 3). Similar findings were observed in both
CD8highCD56 and CD56 T-cell subsets. In contrast, the
frequencies of IFN-–, IL-4-, and IL-10–producing cells did not
change markedly in CD56 T-cell subsets after treatment (Ta-
ble 3). As shown in Table 1, three patients showed only slight
clinical improvement (anterior chamber cells  1) after 2
months of Cs/Pd treatment. In these patients, the level of
IFN-–producing CD56 T cells did not change significantly,
though the population of CD56 T cells decreased significantly
after Cs/Pd treatment.
Elevation of IL-4 Levels in Serum
by Cs/Pd Treatment
Pretreatment levels of IFN- and IL-4 in both aqueous humor
and serum were higher in patients than in healthy control
subjects (Fig. 4). In addition, the levels of IFN- and IL-4 in
aqueous humor were much higher than in serum from the
same patients. Serum levels of IL-4 were significantly elevated
by treatment (30  17 pg/mL vs. 127  38 pg/mL, P  0.01).
Levels of IL-10 in aqueous humor and serum were below the
detection limit (1.5 pg/mL) in all patients with Behçet’s
uveitis and remained low in serum after treatment.
FIGURE 2. Representative flow cy-
tometry showing the downregula-
tion of CD56 expression on CD3 T
cells in patients with Behçet’s uveitis
in response to combined cyclospor-
ine and prednisone treatment. Four-
or three-color staining of peripheral
blood mononuclear cells with anti-
CD3, CD4, CD8, CD56,  TCR, and
V24 mAbs was performed in healthy
control subjects and in patients with
Behçet’s. Pretreatment, upregulated
CD56 T-cell subsets (bold numbers)
including CD3CD56, CD4CD56,
CD8highCD56, and CD56 T cells
were downregulated after treatment.
TABLE 3. Intracellular Cytokine Staining of Lymphocyte Subsets in Patients with Behçet’s Ureitis before









IFN- 14  6 23  7* 21  19
IL-4 0.8  0.8 0.5  0.3 0.6  0.7
IL-10 0.1  0.1 0.1  0.1 0.1  0.1
CD3CD56 stimulated
IFN- 19  10 47  13* 29  21†
IL-4 2.7  1.3 0.4  0.2* 3.4  1.5†
IL-10 2.5  0.9 0.7  0.3* 3.0  2.4†
CD56 stimulated
IFN- 18  10 46  17* 31  12†
IL-4 3.0  1.6 0.4  0.5* 4.9  1.2†
IL-10 1.0  0.4 0.6  0.5 1.2  1.1
CD8highCD56 stimulated
IFN- 20  6 52  11* 28  18†
IL-4 1.0  0.5 0.5  0.3* 3.4  1.8†
IL-10 2.5  1.4 0.9  0.6* 3.2  1.8†
Significant difference from healthy controls (*) or pre-treatment values (†).
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DISCUSSION
In this study, we found that the IFN-–producing CD56 T
cells are elevated in patients with active Behçet’s uveitis, illus-
trating that IFN-–producing CD56 T cells are a pathogenic
T-cell subset in the disease. This increase in cell population
mainly consisted of CD8highCD56 and CD56 T cells rather
than CD4CD56 and V24CD56 T cells. Moreover, we
found that the elevated CD56 T-cell count in the pretreat-
ment stage reduced to the normal level in response to Cs/Pd
treatment, without significant changes in total T lymphocytes
and CD56 T cells. Although several studies have reported that
CD3, CD4, CD8low, and  T cells coexpressing CD56 are
increased in Behçet’s disease,9,10,20,21 few prospective studies
have been conducted to investigate phenotypic changes in the
same patients after Cs/Pd treatment.
Our results show that CD56 expression on circulating T
cells may be a useful marker for monitoring the therapeutic
effects of Cs/Pd treatment in patients with Behçet’s uveitis. A
recent study in a T-cell-mediated autoimmune disease sug-
gested that CD56 expression may reflect the aggressiveness of
autoreactive effector T cells.13 Satoh et al.,12 reported that
cytotoxic  or  T cells coexpressing CD56 are induced
from human peripheral blood lymphocytes in a Th1 dominant
microenvironment. It has also been reported that IL-12, a
possible Th1 cytokine that augments the cytotoxic functions of
CD56 T cells, is increased in the aqueous humor and vitreous
samples of patients with uveitis.22 We also showed that the
aqueous humor of patients with active Behçet’s uveitis is rich
in IFN-, a representative Th1 cytokine. Thus, the increased
circulating CD56 T cells in our patients may harm ocular
structures after infiltrating the eye. One may suspect that the
CD56 T cells in our study were a subset of cytokine-induced
killer cells. However, CD56 T cells may differ from cytokine-
induced natural killer cells because of the presence of TCR and
FIGURE 3. Histograms of the results of flow cytometric analysis of intracellular cytokines in CD3CD56, CD3CD56, CD8highCD56, and
CD8highCD56 cells. PBMCs of healthy control subjects and patients with Behçet’s uveitis were stimulated with phorbol myristate acetate and
calcium ionomycin and stained for intracellular cytokines (IFN-, IL-4, and IL-10) and surface markers (CD3, CD8, and CD56). Bold numbers:
significant difference from the control subjects or pretreatment levels (P  0.05).
FIGURE 4. Cytokine levels in aque-
ous humor (A) and serum (B) in 10
healthy control subjects and in 10
patients with Behçet’s. The aqueous
humor and serum were drawn from
the same subject. Patients were treated
with Cs and Pd. *Significantly differ-
ent from healthy control subjects.
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high expression levels of CD8. They can be derived from the
conventional CD56 T cells by chronic antigenic stimulation
and designated as a cytolytic effector T cells.12,23,24 Moreover,
NK receptors like CD56 are expressed on subsets of effector T
cells, particularly those that have replicated extensively, and
may act as costimulatory signals mediated through the T-cell
antigen receptor.25
Our results regarding cytokine production in active Beh-
çet’s uveitis are in line with those in previous reports8,17,26 and
confirm that a strong Th1-polarized cellular immune response
could play a critical role in disease pathogenesis. The fre-
quency of IFN-–producing T cells increased in our patients
with active Behçet’s uveitis. IFN-, a representative Th1 cyto-
kine, was reported to promote cytotoxic CD8 T cell-mediated
target cell destruction through the upregulation of MHC class
I expression and to induce NO, which is cytotoxic to vascular
endothelial cells.27,28 We also found that levels of IFN- were
elevated in both the aqueous humor and serum of patients with
Behçet’s uveitis. Furthermore, the levels of IFN- were much
higher in aqueous humor than in serum, which indicates that
it may be actively produced in eyes with Behçet’s uveitis.
In this study, our intracellular cytokine staining showed that
IFN- production was increased in both CD56 and CD56 T
cells compared with healthy control subjects, but augmented
by CD56 T-cell subsets such as CD8highCD56 and CD56
T cells more than CD56 T cells. Cs/Pd treatment suppressed
IFN- production in CD56 T-cell subsets rather than CD56 T
cells. This suppression may be attributed to IL-2 gene expres-
sion inhibition by Cs, because cytokine production in CD56
T cells has been reported to be more dependent on IL-2 than
CD56 T cells.29 Moreover, inducible NK receptors appear on
subsets of rapidly proliferating effector T cells, which are more
sensitive to treatment.25 However, the increased IFN- produc-
tion did not return to normal levels. This may be explained in
part by suggestions that T cells in Behçet’s disease respond to
specific or nonspecific stimulation in a hypersensitive manner
because of intrinsic T-cell defects.30 Thus, it is conceivable that
some of the hypersensitivity may remain after treatment, be-
cause Cs/Pd treatment does not completely restore these un-
derlying defects.
IL-4 and -10, two representative Th2 cytokines, were mark-
edly lower in the CD56 T cells of pretreated patients with
Behçet’s, though levels normalized after treatment. In contrast,
CD56 T cells did not reveal any significant difference in
cytokine production, irrespective of inflammation. This implies
that CD56 T cells play a major role in the immunopathogen-
esis of and in recovery from Behçet’s uveitis. IL-4 production
by CD56 T cells and the serum levels of IL-4 were significantly
increased by Cs/Pd treatment, and the resultant levels were
higher than those in the control subjects. These results suggest
that Th2 immune responses may not be inhibited but are
somewhat augmented by Cs/Pd treatment. Previous studies on
cytokine profiles in patients with Behçet’s revealed that IL-4–
producing cells and serum concentrations were elevated irre-
spective of inflammatory activity.31,32 This difference regard-
ing IL-4 production and inflammatory activity may reflect
different stages of the immunologic processes or the inclusion
of patients undergoing ongoing immunosuppressive treatment.
This study enrolled only patients with Behçet’s who had severe
panuveitis and had not received immunosuppressive treatment
within 1 month of the study’s commencement. Thus, our
results show a relatively consistent distribution of lymphocyte
subset percentages and cytokine profiles. It may be concluded
that Cs/Pd treatment in Behçet’s uveitis selectively suppresses
Th1 immune response and aids the restoration of the underly-
ing Th2 responses. However, further study is needed to deter-
mine whether the Th2 immune response plays a protective
role in Behçet’s disease.
We also found that attenuated populations of CD4 cells in
patients with Behçet’s uveitis normalized after Cs/Pd treat-
ment. Sakane et al.,33 reported that the CD4-CD8 cell ratio
was reduced in patients with Behçet’s, as a result of a decrease
in CD4 cells and a concomitant increase in CD8 cells. The
CD4-CD8 ratio normalized during the inactive phase. The
similar number of CD8highCD56 T cells between control
subjects and patients, irrespective of treatment, indicates that
increased populations of CD8high T cells express CD56. In this
study,  T cells with or without CD56 were increased in
patients with active Behçet’s uveitis.  T cells are well known
to increase in the peripheral blood of patients with Behçet’s
with mucocutaneous manifestations and to correlate with dis-
ease activity.34,35 Although functional differences between
CD56 and CD56 T cells in patients with Behçet’s are not
clear, CD56 expression may be associated with the potent
cytotoxic activity, since it can be induced from  T cells in
IL-2- and -12-rich microenvironments.12 In our patients,
CD56 T cells showed more dramatic changes in the pop-
ulation and cytokine production after treatment than did the
CD56 subset, thus implying that Cs/Pd treatment affects both
 and CD56 T cells rather than CD56 T cells. In
addition, the finding that total lymphocyte count did not
change after Cs/Pd treatment confirms that Cs use does not
result in leukopenia.36
In summary, the populations and IFN- production by
CD56 T-cell subsets were increased in patients with active
Behçet’s uveitis, but normalized after combined low-dose
Cs/Pd treatment without significant changes in total T lympho-
cyte counts and CD56 T cells. These results imply that IFN-
–producing CD56 T cells are important pathogenic immune
cells and that current Cs/Pd treatment for Behçet’s disease
selectively affects the CD56 T-cell subset.
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